Get the Stockscreener App
20.85
3.12%
0.63
Aktis Oncology Inc stock is traded at $20.85, with a volume of 189.56K.
It is up +3.12% in the last 24 hours and up +4.67% over the past month.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
See More
Previous Close:
$20.22
Open:
$20.51
24h Volume:
189.56K
Relative Volume:
0.01
Market Cap:
$1.15B
Revenue:
$29.71M
Net Income/Loss:
$-69.15M
P/E Ratio:
-21.49
EPS:
-0.97
Net Cash Flow:
$-52.28M
1W Performance:
+6.92%
1M Performance:
+4.67%
6M Performance:
+55,948%
1Y Performance:
+55,948%
1-Day Range:
$19.93
$21.15
1-Week Range:
$18.93
$21.15
52-Week Range:
$16.80
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Compare AKTS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
20.85 | 1.12B | 29.71M | -69.15M | -52.28M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | BofA Securities | Buy |
| Feb-03-26 | Initiated | JP Morgan | Overweight |
| Feb-03-26 | Initiated | Leerink Partners | Outperform |
| Feb-03-26 | Initiated | TD Cowen | Buy |
| Jan-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-06-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-24-23 | Initiated | B. Riley Securities | Buy |
| Feb-02-21 | Reiterated | Craig Hallum | Buy |
| Jan-15-21 | Reiterated | Craig Hallum | Buy |
| Sep-18-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-10-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-13-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Dec-18-18 | Initiated | Craig Hallum | Buy |
| Nov-30-18 | Initiated | Lake Street | Buy |
| Jun-22-18 | Initiated | Loop Capital | Buy |
| Feb-09-18 | Initiated | Drexel Hamilton | Buy |
View All
Aktis Oncology Inc Stock (AKTS) Latest News
Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors - TipRanks
AKTS: New miniprotein radiopharmaceuticals target broad solid tumor markets, advancing in clinic - TradingView
AKTS: Lead radiopharmaceutical assets advance toward major milestones in a rapidly expanding market - TradingView
BUDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKTS Technical Analysis & Stock Price Forecast - Intellectia AI
IPO Tracker 2026: Generate Clocks Largest IPO Since 2024 With $400M Raise - BioSpace
Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Yahoo Finance
Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target - TipRanks
Aktis Oncology to Present at Upcoming March Investor Conferences - The Manila Times
Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Bitget
Aktis Oncology receives U.S. FDA fast track designation for Aky-1189 - marketscreener.com
Aktis Oncology's AKY-1189 Wins FDA Fast Track Designation - Nasdaq
Flagship-Backed Generate Bio Seeks $425 Million in US IPO - Bloomberg.com
Flagship-Backed Generate Biomedicines Seeks $425 Million in IPO - Bloomberg.com
Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO - Reuters
Ken Herrmann Net Worth (2026) - GuruFocus
US Index IPO ForecastMar26: 8 Additions Including Medline & BETA Technologies - Smartkarma
Huge insider buying now at this insurance giant and 2 biotechs - MSN
2026 kicks off with $10.8B January financing haul - BioWorld MedTech
Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut - WTVB
Eikon’s $381M raise represents largest biopharma IPO in two years - BioWorld MedTech
Eikon Therapeutics raises $381M in IPO - Axios
Merck Veteran-Led Eikon Therapeutics Raises $381 Million in IPO - Bloomberg.com
Biopharma Co.'s Down-Round IPO May Signal More To Come - Law360
This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - Benzinga
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential - TipRanks
Merck veteran Perlmutter-led Eikon Therapeutics eyes $908 million valuation in IPO - Reuters
Eikon ?Therapeutics targets $908 million valuation in US IPO - marketscreener.com
Eikon sets $274M goal for upcoming stock market debut - Fierce Biotech
Carvina Capital: Strong Demand Lifts Aktis IPO - Barchart.com
Aktis Oncology prices IPO at $18 per share - MSN
Why Revolution Medicines Stock Surged by 11% Today - AOL.com
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - AOL.com
Investors Scoop Up Shares in Key Insurance and Biotech Companies - finance.coin-turk.com
‘No reasons to own’: Software stocks sink on fear of new AI tool - The Japan Times
Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying - Yahoo Finance
AKTS SEC FilingsAKTIS ONCOLOGY INC 10-K, 10-Q, 8-K Forms - Stock Titan
United StatesGoodwin Advises Aktis Oncology In Closing Of $365.4 Million Upsized Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack - Investing.com Nigeria
Wednesday Insider Activity: Mitsui’s $55.6M Berkley Buy Leads the Pack By Investing.com - Investing.com South Africa
Biotech Venture Limped Through 2025. A Brighter 2026 Beckons. - The Wall Street Journal
Insiders Make Bold Move as Key Players Double Down on Aktis Oncology - TipRanks
Aktis Oncology director Foley buys $4.19 million in shares By Investing.com - Investing.com India
Aktis Oncology: Mpm funds buy shares worth $20m By Investing.com - Investing.com Nigeria
Aktis Oncology: Mpm funds buy shares worth $20m - Investing.com
Aktis Oncology (AKTS) sees $20 million purchase by 10% owner - Investing.com South Africa
Aktis Oncology Inc Stock (AKTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):